Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00884793 · ClinicalTrials.gov registry record · NA

Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut

A NA study of HIV Infections, sponsored by University of California, San Francisco.

Completed
Registry status
NA
Development phase
8
Enrollment target
2
Study locations

NCT00884793 is a NA study of HIV Infections that has completed, run by University of California, San Francisco. The registered enrollment target is 8 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00884793, a NA study of HIV Infections, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
NA
Development phase
8 participants
Enrollment target
2
Study locations

Study Summary

The "PLUS" study is a pilot study to measure the effect of therapy intensification (with raltegravir and optional second agent) on HIV levels in the gut and blood in patients on antiretroviral therapy (ART) with viral load \< 50 copies/mL (herein referred to as "suppressed"). We hypothesize that there is ongoing replication in the gut despite suppressive ART and that this replication can be inhibited by the addition of one or two new antiretroviral drugs whose activity affects a distinct part of the viral life cycle. All study participants will have upper and lower endoscopy at baseline (before intensification) and after intensification. These endoscopies will be used to obtain gut tissue and single cells (for CD4+ cells) .

Conditions Studied

HIV Infections

Interventions

  • DRUG raltegravir
  • DRUG Study NNRTI
  • DRUG Study PI

Study Locations (2)

California

  • San Francisco General Hospital - San Francisco
  • San Francisco VA Medical Center (SFVAMC) - San Francisco

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2008-09
Est. Completion 2010-12
Phase NA

Sponsor

University of California, San Francisco

1,713 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00884793

The ClinicalTrials.gov registry entry for NCT00884793 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (98% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which raltegravir is the first listed.

NCT00884793 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00884793 about?

NCT00884793 is a clinical study titled "Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut". The "PLUS" study is a pilot study to measure the effect of therapy intensification (with raltegravir and optional second agent) on HIV levels in the gut and blood in patients on antiretroviral therapy (ART) with viral load \< 50 copies/mL (herein referred to as "suppressed"). We hypothesize that the...

What is the current status of trial NCT00884793?

This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2008-09. Estimated completion is 2010-12.

What conditions does trial NCT00884793 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00884793?

The interventions under investigation include: raltegravir (DRUG), Study NNRTI (DRUG), Study PI (DRUG).

Who is sponsoring clinical trial NCT00884793?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00884793 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.